56121-44-9

Usage

Uses

Used in Pharmaceutical Industry:
2',4'-Dihydroxy-4,6'-dimethoxychalcone is used as a pharmaceutical candidate for its antioxidant and anti-inflammatory properties, making it suitable for the development of new drugs and nutraceuticals with potential health benefits.
Used in Cancer Prevention and Treatment:
2',4'-Dihydroxy-4,6'-dimethoxychalcone is used as an anticancer agent for its potential in preventing and treating various types of cancer. Its biological activities contribute to the modulation of oncological signaling pathways, exerting inhibitory effects on tumor growth and progression.
Used in Cardiovascular Disease Prevention and Treatment:
2',4'-Dihydroxy-4,6'-dimethoxychalcone is used as a preventive and therapeutic agent for cardiovascular diseases, leveraging its antioxidant properties to protect against oxidative stress and inflammation associated with these conditions.
Used in Neurodegenerative Disorder Prevention and Treatment:
2',4'-Dihydroxy-4,6'-dimethoxychalcone is used as a potential treatment for neurodegenerative disorders, with its antioxidant and anti-inflammatory properties potentially mitigating the effects of oxidative stress and inflammation in the brain.
Used in Inflammatory Condition Treatment:
2',4'-Dihydroxy-4,6'-dimethoxychalcone is used as an anti-inflammatory agent for the treatment of various inflammatory conditions, capitalizing on its ability to reduce inflammation and associated symptoms.

Upstream product

• 119136-14-0 2,4-bis(benzyloxy)-6-methoxyacetophenone 
• 123-11-5 4-methoxy-benzaldehyde 
• 39548-89-5 1-(4-(benzyloxy)-2-hydroxy-6-methoxyphenyl)ethan-1-one 
• 404597-93-9 1-(2-hydroxy-6-methoxy-4-(methoxymethoxy)phenyl)ethanone 
• 65490-09-7 2'-hydroxy-4',6'-bis(methoxymethoxy)acetophenone 
• 480-66-0 2,4,6-trihydroxyacetophenone 
• 404597-92-8 (E)-1-(2-hydroxy-6-methoxy-4-(methoxymethoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one 
• 84457-62-5 2'-hydroxy-4'-benzyloxy-4,6'-dimethoxychalkone 
• 90-24-4 2-hydroxy-4,6-dimethoxyacetophenone 
• 3602-54-8 4,6-dihydroxy-2-methoxyacetophenone 
• 108-73-6 3,5-dihydroxyphenol 
• 1082076-62-7 (2E)-1-(2,4-di(methoxymethoxy)-6-methoxyphenyl)-3-(4-methoxyphenyl)-2-propen-1-one 
• 1070781-84-8 (2E)-1-[2-methoxy-4,6-bis(2-propenyloxy)phenyl]-3-(4-methoxyphenyl)-2-propen-1-one 

Downstream Products

• 75679-58-2 2’,4’-dihydroxy-4,6’-dimethoxydihydrochalcone 
• 3791-75-1 2'-hydroxy-4,4',6'-trimethoxydihydrochalcone 
• 75679-64-0 2'-acetoxy-4,4',6'-trimethoxydihydrochalkone 
• 75679-63-9 2',4'-diacetoxy-4,6'-dimethoxydihydrochalkone 
• 68939-22-0 7-hydroxy-5-methoxy-3-(4-methoxyphenyl)-4H-chromen-4-one 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of dimethyl cardamonin (DMC) derivatives as P-glycoprotein-mediated multidrug resistance reversal agents

Background: P-glycoprotein (P-gp) has been regarded as an important factor in the multidrug resistance (MDR) of tumor cells within the last decade, which can be solved by inhibiting P-gp to reverse MDR. Thus, it is an effective strategy to develop inhibitor of P-gp. Objective: In this study, the synthesis of a series of derivatives had been carried out by bioisosterism design on the basis of Dimethyl Cardamonin (DMC). Subsequently, we evaluated their reversal activities as potential P-glycoprotein (P-gp)-mediated Multidrug Resistance (MDR) agents. Methods: Dimethyl cardamonin derivatives were synthesized from acetophenones and the corresponding benzaldehydes in the presence of 40% KOH by Claisen-Schmidt reaction. Their cytotoxicity and reversal activities in vitro were assessed with MTT. Moreover, the compound B4 was evaluated by Doxorubicin (DOX) accumulation, Western blot and wound-healing assays deeply. Results and Discussion: The results showed that compounds B2, B4 and B6 had the potency of MDR reversers with little intrinsic cytotoxicity. Meanwhile, these compounds also demonstrated the capability to inhibit MCF-7 and MCF-7/DOX cells migration. Besides, the most compound B4 was selected for further study, which promoted the accumulation of DOX in MCF-7/DOX cells and inhibited the expressionof P-gp at protein levels. Conclusion: The above findings may provide new insights for the research and development of P-gp-mediated MDR reversal agents.

Synthesis of xanthohumol analogues and discovery of potent thioredoxin reductase inhibitor as potential anticancer agent

The selenoprotein thioredoxin reductases (TrxRs) are attractive targets for anticancer drugs development. Xanthohumol (Xn), a naturally occurring polyphenol chalcone from hops, has received increasing attention because of its multiple pharmacological activities. We synthesized Xn and its 43 analogues and discovered that compound 13n displayed the highest cytotoxicity toward HeLa cells (IC50 = 1.4 μM). Structure-activity relationship study indicates that the prenyl group is not necessary for cytotoxicity, and introducing electron-withdrawing group, especially on the meta-position, is favored. In addition, methylation of the phenoxyl groups generally improves the potency. Mechanistic study revealed that 13n selectively inhibits TrxR and induces reactive oxygen species and apoptosis in HeLa cells. Cells overexpressing TrxR are resistant to 13n insult, while knockdown of TrxR sensitizes cells to 13n treatment, highlighting the physiological significance of targeting TrxR by 13n. The clarification of the structural determinants for the potency would guide the design of novel potent molecules for future development.

In vitro and in vivo anti-Leishmania activity of polysubstituted synthetic chalcones

The in vitro screening of 43 polysubstituted chalcones against Leishmania amazonensis axenic amastigotes, led to the evaluation of 9 of them in a macrophage-infected model with the two other most infectious Leishmania species prevalent in Peru (L. braziliensis and L. peruviana). The five most active and selective chalcones were studied in vivo, resulting on the identification of two chalcones with high reduction parasite burden percentages.

COMPOUNDS, THEIR SYNTHESES, AND THEIR USES

Embodiments of the present invention provide compounds (such as Formula (I) compounds, Formula (II) compounds, and various embodiments thereof). Compositions comprising those compounds are also provided. Methods for their preparation are included. Also, uses of the compounds are included, such as administering and treating diseases (e.g., cancer and infections).

Synthesis, cytotoxicity, and anti-Trypanosoma cruzi activity of new chalcones

Synthesis of a cytotoxic dihydrochalcone, first isolated from a traditional Amazonian medicinal plant Iryanthera juruensis Warb (Myristicaceae), followed by a comprehensive SAR analysis of saturated and unsaturated chalcone synthetic intermediates, led to the identification of analogues with selective and significant in vitro anti-Trypanosoma cruzi activity. Further SAR studies were undertaken with the synthesis of 21 new chalcones containing two allyloxy moieties that resulted in the discovery of 2′,4′-diallyloxy- 6′-methoxy chalcones with improved selectivity against this parasite at concentrations below 25 μM, four of which exhibited a selectivity index greater than 12.

A facile synthetic route to two chalcones

A facile total synthetic route to two naturally occurring chalcones with a partially methylated structure has been achieved in good yield. The key step was selective deprotection of a MOM ether in the aryl methyl ether 6 by a solid phase reaction.

Syntheses of Two New Naturally Occurring Dihydrochalkones, Uvangolatin and 2',4'-Dihydroxy-4,6'-dimethoxydihydrochalkone

The structures proposed for the two naturally occurring dihydrochalkones, uvangolatin isolated from Uvaria angolensis as 2',4'-dihydroxy-6'-methoxydihydrochalkone (I) and another dihydrochalkone isolated from Iryanthera laevis as 2',4'-dihydroxy-4,6'-dime